2022 annual financial data

Spero Therapeutics 2022 Net margin

Spero Therapeutics 2022 net margin with verified reported values.

Direct answer

Net margin was -95.55%.

Operating income was -42,197,000 USD and net income was -46,415,000 USD.
Operating cash flow was -7,731,000 USD.

Get free Spero Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
48,579,000 USD
Operating income
-42,197,000 USD
Net income
-46,415,000 USD
Operating cash flow
-7,731,000 USD